CA2600301A1 - Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition - Google Patents
Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition Download PDFInfo
- Publication number
- CA2600301A1 CA2600301A1 CA002600301A CA2600301A CA2600301A1 CA 2600301 A1 CA2600301 A1 CA 2600301A1 CA 002600301 A CA002600301 A CA 002600301A CA 2600301 A CA2600301 A CA 2600301A CA 2600301 A1 CA2600301 A1 CA 2600301A1
- Authority
- CA
- Canada
- Prior art keywords
- increasing
- extract
- subject
- composition according
- thermogenesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 238000000034 method Methods 0.000 title claims abstract description 27
- 230000035924 thermogenesis Effects 0.000 title claims abstract description 20
- 230000003387 muscular Effects 0.000 title abstract description 11
- 230000004060 metabolic process Effects 0.000 title description 2
- 230000037323 metabolic rate Effects 0.000 claims abstract description 17
- 230000003247 decreasing effect Effects 0.000 claims abstract description 16
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 16
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims abstract description 12
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract description 10
- GEPMAHVDJHFBJI-UHFFFAOYSA-N 7-[2-hydroxy-3-[2-hydroxyethyl(methyl)amino]propyl]-1,3-dimethylpurine-2,6-dione;pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2CC(O)CN(CCO)C GEPMAHVDJHFBJI-UHFFFAOYSA-N 0.000 claims abstract description 8
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000020688 green tea extract Nutrition 0.000 claims abstract description 8
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 8
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 8
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 8
- 235000008160 pyridoxine Nutrition 0.000 claims abstract description 8
- 239000011677 pyridoxine Substances 0.000 claims abstract description 8
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 8
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims abstract description 7
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims abstract description 7
- 229940094952 green tea extract Drugs 0.000 claims abstract description 7
- CAHKINHBCWCHCF-JTQLQIEISA-N N-acetyl-L-tyrosine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CAHKINHBCWCHCF-JTQLQIEISA-N 0.000 claims abstract description 6
- 229960001948 caffeine Drugs 0.000 claims abstract description 6
- 229960001682 n-acetyltyrosine Drugs 0.000 claims abstract description 6
- 235000019157 thiamine Nutrition 0.000 claims abstract description 6
- 239000011721 thiamine Substances 0.000 claims abstract description 6
- 229940107681 dandelion root extract Drugs 0.000 claims abstract description 5
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 235000020733 paullinia cupana extract Nutrition 0.000 claims description 4
- 229960004855 xantinol nicotinate Drugs 0.000 claims description 2
- 239000000843 powder Substances 0.000 abstract description 28
- 239000000284 extract Substances 0.000 abstract description 25
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 abstract description 8
- 240000004160 Capsicum annuum Species 0.000 abstract description 6
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 abstract description 6
- 235000002283 Capsicum annuum var aviculare Nutrition 0.000 abstract description 6
- 235000013303 Capsicum annuum var. frutescens Nutrition 0.000 abstract description 6
- 235000002284 Capsicum baccatum var baccatum Nutrition 0.000 abstract description 6
- 235000002568 Capsicum frutescens Nutrition 0.000 abstract description 6
- 241000911175 Citharexylum caudatum Species 0.000 abstract description 6
- 244000188472 Ilex paraguariensis Species 0.000 abstract description 6
- 235000003368 Ilex paraguariensis Nutrition 0.000 abstract description 6
- 235000006468 Thea sinensis Nutrition 0.000 abstract description 6
- 240000006474 Theobroma bicolor Species 0.000 abstract description 6
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 abstract description 6
- 239000000177 juniperus communis l. berry Substances 0.000 abstract description 6
- 235000020333 oolong tea Nutrition 0.000 abstract description 6
- 235000011197 perejil Nutrition 0.000 abstract description 6
- 229960000744 vinpocetine Drugs 0.000 abstract description 6
- 235000020334 white tea Nutrition 0.000 abstract description 6
- 240000003444 Paullinia cupana Species 0.000 abstract description 4
- 235000000556 Paullinia cupana Nutrition 0.000 abstract description 4
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 abstract description 4
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 abstract description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 abstract description 4
- 235000005875 quercetin Nutrition 0.000 abstract description 4
- 229960001285 quercetin Drugs 0.000 abstract description 4
- -1 picamilone Chemical compound 0.000 abstract description 3
- 240000009164 Petroselinum crispum Species 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 7
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 239000013589 supplement Substances 0.000 description 6
- 241000208317 Petroselinum Species 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 241000245665 Taraxacum Species 0.000 description 2
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000000476 thermogenic effect Effects 0.000 description 2
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 235000010215 titanium dioxide Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 244000119461 Garcinia xanthochymus Species 0.000 description 1
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Compositions and methods for administering the same to humans are provided for the promotion of increasing a person's natural metabolic rate, increasing thermogenesis, increasing training intensity, increasing muscular definition, and/or decreasing water retention. Said compositions comprise, green tea extract, anhydrous caffeine, theobroma cocao extract, oolong tea extract, white tea extract, guarana, yerba mate powder, dandelion root extract, juniper berry powder, parsley powder garcinia cambogia extract, cayenne pepper powder extract, n-acetyl-l-tyrosine, quercetin dehydrate, gynostemma pentaphyullum extract, vinpocetine and optionally thiamin, pyridoxine, picamilone, xanthinol nicotinate, garcinia cambogia extract and niacin.
Description
Compositions and Methods for Increasing Metabolism, Thermogenesis and/or Muscular Definition Field of the Invention The present invention relates to compositions and methods for increasing a person's natural metabolic rate, increasing thermogenesis or decreasing water retention.
Summary of the Invention In one aspect, the present invention comprises a composition of a first combination that comprises green tea extract, anhydrous caffeine, and guarana powder; a second combination that comprises dandelion root extract, and juniper berry powder;
and a third combination that comprises N-acetyl-L-tyrosine, and gynostemma pentaphyullum.
Additionally, the present invention may also comprise thiamin, pyridoxine, niacin, quercetin dehydrate, cayenne pepper powder, oolong tea extract, white tea extract, theobroma cocao extract, vinpocetine, yerba mate leaf powder, parsley powder extract, picamilone, and xanthinol nicotinate. In another aspect, the present invention provides methods for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention in a subject utilizing the invention. In another aspect, the present invention provides methods of reducing body fat mass leading to weight loss and improving muscular definition in subjects.
Detailed Description of the Invention The present invention, according to one embodiment, provides a composition for increasing a subject's natural metabolic rate and/or decreasing water retention, thus reducing a subject's body fat mass leading to weight loss and improving visible muscular definition. Certain embodiments of the present invention include diet supplements. According to other embodiments of the present invention, there is provided a composition that reduces body fat mass leading to weight loss, thus improving muscular definition. In one embodiment the present invention may allow a subject to burn more calories than the subject would otherwise burn (dramatically increasing thermogenesis), thereby reducing body fat mass leading to weight loss.
In another embodiment the present invention provides compositions and methods that decrease water retention in subjects. For example, the composition and method may provide a diuretic effect causing a person to retain less water than the person would otherwise retain, thereby providing weight loss and improving muscular definition.
In certain embodiments of the present invention, a composition and related methods comprise:
a first combination of one or more of theobroma extract, green tea extract, oolong tea extract, white tea extract, anhydrous caffeine, niacin, and yerba mate extract, and guarana extract;
a second combination of one or more of dandelion root extract, juniper berry powder, parsley powder (leaf) and cayenne pepper powder;
a third combination of one or more of N-acetyl-L-tyrosine, gynostemma pentaphyullum extract, and vinpocetine. Additionally, the present invention may also comprise thiamin, pyridoxine, picamilone, garcinia cambogia, and/or xanthinol nicotinate. In another embodiment, the present invention may further comprise ingredients such as, thiamin or any salts or esters thereof, niacin, xantinol nicotinate, picamilone, and pyridoxine or a salt thereof in any of its pharmaceutically acceptable forms.
Compounds according to the present invention have been shown to have thermogenic effects. Catechin epigallocatechin-3-gallate (EGCG), a component of green tea, has been shown to possess the ability to give to rise to thermogenic effects.
In one study (Berube-Parent S, Pelletier C, Dore J, Tremblay A. (2005) "Effects of encapsulated green tea and Guarana extracts containing a mixture of epigallocatechin-3-gailate and caffeine on 24 h energy expenditure and fat oxidation in men."
Br J Nutr.
Sep;94(3):432-6.) the energy expenditure and fat oxidation over a 24-hour time period employing components of the present invention was observed. Fourteen subjects took part in a randomized, placebo-controlled, double blind, crossover study. Each subject was tested 5 times in a metabolic chamber to measure 24-hour energy expenditure, substrate oxidation and blood pressure. During each stay, the subjects ingested a placebo or capsules containing components of the present invention 30 minutes before standardized meals. It was found that 24-hour energy expenditure increased significantly by about 750 kJ within all the treatment groups compared to placebo. This study found an increase in the 24-hour energy expenditure in the treatment groups. The resultant increase in energy expenditure via treatment with components comprising the present invention leads to an increase in the natural metabolic rate, the burning of calories, and an increase in thermogenesis.
Where the composition is in the nature of a diet supplement, the diet supplement may be consumed in any form. For instance, the dosage form of the diet supplement may be as a powder beverage mix, a liquid beverage, a ready-to-eat bar or drink product, a capsule, a tablet, a capiet, or as a dietary gel.
Furthermore, the dosage form of the diet supplement in accordance with these embodiments may be provided in accordance with customary processing techniques for herbal and/or diet supplements in any of the forms mentioned above.
In one embodiment of the present invention, which is set forth in greater detail in Example 1 below, a composition is provided for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention.
In a second embodiment of the present invention, which is set forth in greater detail in Example 2 below, a composition is provided for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention.
The compositions according to the present invention may be employed in methods for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention in subjects. The compositions of the present invention are particularly advantageous for athletes and bodybuilders to improve muscular definition. The dosage amount of the compositions according to the present invention which is administered to a subject may vary depending on the desired effect, the body weight and other characteristics of the subject. For example, in various embodiments, the compositions according to the present invention are administered to the subject on a daily basis. In another embodiment the compositions according to the present invention are administered to the subject three times daily.
The present invention also provides a method of increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention in a subject. In one embodiment, the methods of the present invention include administering a composition to a subject. According to another embodiment of the present invention, methods for reducing body fat mass leading to weight loss and thus improving visible muscular definition are provided. In one embodiment , the administration of compositions according to the present invention allow a person's body to burn more calories than the person's body would otherwise burn (dramatically increasing thermogenesis), thereby reducing body fat mass leading to weight loss.
In example embodiments set forth below, the methods of the present invention provide for the administration of compositions according to the present invention that decrease water retention. For example, the administration of compositions according to the present invention may provide a diuretic effect causing a person to retain less water than the person would otherwise retain, thereby providing weight loss and improving muscular definition.
In embodiments described in the examples below, compositions and related methods comprising a first combination of one or more of theobroma extract, green tea extract, oolong tea extract, white tea extract, caffeine, niacin, and yerba mate extract, and guarana extract;
a second combination of one more of dandelion root extract, juniper berry powder, parsley powder (leaf), cayenne pepper powder, and xanthinol nicotinate;
a third combination of one or more of N-acetyl-L-tyrosine, gynostemma pentaphyullum extract, and vinpocetine. Additionally, the present invention may also comprise thiamin, pyridoxine, picamilone, garcinia cambogia extract, and/or xanthinol nicotinate.
The compositions according to the present invention may be administered in methods for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention. The methods of the present invention are particularly advantageous for athletes and bodybuilders to improve visible muscular definition. In certain embodiments, the methods of the present invention include a determination, and an administration, of an amount of a composition in accordance with factors such as the desired effect, the body weight and characteristics of the athlete. For example, in certain embodiments, the present invention includes methods of administering compositions according to the invention to subjects on a daily basis or three times daily.
Although the following example illustrates the practice of the present invention in example embodiments, the examples should not be construed as limiting the scope of the invention. Other embodiments will be apparent to one skilled in the art from consideration of the specification and example.
Example 1 As a first example, the following composition is provided: green tea extract (0.4440 g), caffeine anhydrous (0.3000 g), dandelion root powder (0.2500 g), parsley powder (0.2000 g), juniper berry powder (0.2000 g), cayenne pepper powder (0.1000 g), n-acetyl-l-tyrosine (0.1000 g), quercetin dehydrate (0.1000 g), picamilone HCI
(0.1000 g), gynostemma pentaphyullum leaf exact (0.0350 g), niacin (0.0330 g), oolong tea dry leaf extract (0.0100 g), white tea dry leaf extract (0.0100 g), theobroma cocao extract (0.0100 g), vinpocetine (0.0050 g), pyridoxine HCI (0.0020 g), thiamin mononitrate (0.0015 g), guarana powder (0.0010 g), yerba mate leaf powder (0.0010 g), gelatin, titanium dioxide, microcrystalline cellulose (0.0660 g), magnesium stearate (0.0330 g), and silica (0.0165 g).
The example composition may be ingested 30 to 60 minutes prior to eating a meal. The example composition can also be consumed prior exercise to increase and athlete's training intensity.
Example 2 As a second example, the following composition is provided: green tea extract (0.440 g), caffeine anhydrous (0.3000 g), dandelion root powder (0.2500 g), parsley powder (0.2000 g), juniper berry powder (0.200), cayenne pepper powder (0.100 g), n-acetyl-I-tyrosine (0.1000 g), quercetin dehydrate (0.1000 g), xanthinol nicotinate (0.1000 g), gynostemma pentaphyullum leaf exact (0.0350 g), niacin (0.0330 g), oolong tea dry leaf extract (0.0100 g), white tea dry leaf extract (0.0100 g), theobroma cocao extract (0.0100 g), vinpocetine (0.0050 g), pyridoxine HCI (0.0020 g), thiamin mononitrate (0.0015 g), guarana powder (0.0010 g), yerba mate leaf powder (0.0010), gelatin, titanium dioxide, microcrystalline cellulose (0.0660), magnesium stearate (0.0330 g), and silica (0.0165 g).
The example composition may be ingested 30 to 60 minutes prior to eating a meal. The example composition can also be consumed prior exercise to increase and athlete's training intensity.
Summary of the Invention In one aspect, the present invention comprises a composition of a first combination that comprises green tea extract, anhydrous caffeine, and guarana powder; a second combination that comprises dandelion root extract, and juniper berry powder;
and a third combination that comprises N-acetyl-L-tyrosine, and gynostemma pentaphyullum.
Additionally, the present invention may also comprise thiamin, pyridoxine, niacin, quercetin dehydrate, cayenne pepper powder, oolong tea extract, white tea extract, theobroma cocao extract, vinpocetine, yerba mate leaf powder, parsley powder extract, picamilone, and xanthinol nicotinate. In another aspect, the present invention provides methods for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention in a subject utilizing the invention. In another aspect, the present invention provides methods of reducing body fat mass leading to weight loss and improving muscular definition in subjects.
Detailed Description of the Invention The present invention, according to one embodiment, provides a composition for increasing a subject's natural metabolic rate and/or decreasing water retention, thus reducing a subject's body fat mass leading to weight loss and improving visible muscular definition. Certain embodiments of the present invention include diet supplements. According to other embodiments of the present invention, there is provided a composition that reduces body fat mass leading to weight loss, thus improving muscular definition. In one embodiment the present invention may allow a subject to burn more calories than the subject would otherwise burn (dramatically increasing thermogenesis), thereby reducing body fat mass leading to weight loss.
In another embodiment the present invention provides compositions and methods that decrease water retention in subjects. For example, the composition and method may provide a diuretic effect causing a person to retain less water than the person would otherwise retain, thereby providing weight loss and improving muscular definition.
In certain embodiments of the present invention, a composition and related methods comprise:
a first combination of one or more of theobroma extract, green tea extract, oolong tea extract, white tea extract, anhydrous caffeine, niacin, and yerba mate extract, and guarana extract;
a second combination of one or more of dandelion root extract, juniper berry powder, parsley powder (leaf) and cayenne pepper powder;
a third combination of one or more of N-acetyl-L-tyrosine, gynostemma pentaphyullum extract, and vinpocetine. Additionally, the present invention may also comprise thiamin, pyridoxine, picamilone, garcinia cambogia, and/or xanthinol nicotinate. In another embodiment, the present invention may further comprise ingredients such as, thiamin or any salts or esters thereof, niacin, xantinol nicotinate, picamilone, and pyridoxine or a salt thereof in any of its pharmaceutically acceptable forms.
Compounds according to the present invention have been shown to have thermogenic effects. Catechin epigallocatechin-3-gallate (EGCG), a component of green tea, has been shown to possess the ability to give to rise to thermogenic effects.
In one study (Berube-Parent S, Pelletier C, Dore J, Tremblay A. (2005) "Effects of encapsulated green tea and Guarana extracts containing a mixture of epigallocatechin-3-gailate and caffeine on 24 h energy expenditure and fat oxidation in men."
Br J Nutr.
Sep;94(3):432-6.) the energy expenditure and fat oxidation over a 24-hour time period employing components of the present invention was observed. Fourteen subjects took part in a randomized, placebo-controlled, double blind, crossover study. Each subject was tested 5 times in a metabolic chamber to measure 24-hour energy expenditure, substrate oxidation and blood pressure. During each stay, the subjects ingested a placebo or capsules containing components of the present invention 30 minutes before standardized meals. It was found that 24-hour energy expenditure increased significantly by about 750 kJ within all the treatment groups compared to placebo. This study found an increase in the 24-hour energy expenditure in the treatment groups. The resultant increase in energy expenditure via treatment with components comprising the present invention leads to an increase in the natural metabolic rate, the burning of calories, and an increase in thermogenesis.
Where the composition is in the nature of a diet supplement, the diet supplement may be consumed in any form. For instance, the dosage form of the diet supplement may be as a powder beverage mix, a liquid beverage, a ready-to-eat bar or drink product, a capsule, a tablet, a capiet, or as a dietary gel.
Furthermore, the dosage form of the diet supplement in accordance with these embodiments may be provided in accordance with customary processing techniques for herbal and/or diet supplements in any of the forms mentioned above.
In one embodiment of the present invention, which is set forth in greater detail in Example 1 below, a composition is provided for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention.
In a second embodiment of the present invention, which is set forth in greater detail in Example 2 below, a composition is provided for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention.
The compositions according to the present invention may be employed in methods for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention in subjects. The compositions of the present invention are particularly advantageous for athletes and bodybuilders to improve muscular definition. The dosage amount of the compositions according to the present invention which is administered to a subject may vary depending on the desired effect, the body weight and other characteristics of the subject. For example, in various embodiments, the compositions according to the present invention are administered to the subject on a daily basis. In another embodiment the compositions according to the present invention are administered to the subject three times daily.
The present invention also provides a method of increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention in a subject. In one embodiment, the methods of the present invention include administering a composition to a subject. According to another embodiment of the present invention, methods for reducing body fat mass leading to weight loss and thus improving visible muscular definition are provided. In one embodiment , the administration of compositions according to the present invention allow a person's body to burn more calories than the person's body would otherwise burn (dramatically increasing thermogenesis), thereby reducing body fat mass leading to weight loss.
In example embodiments set forth below, the methods of the present invention provide for the administration of compositions according to the present invention that decrease water retention. For example, the administration of compositions according to the present invention may provide a diuretic effect causing a person to retain less water than the person would otherwise retain, thereby providing weight loss and improving muscular definition.
In embodiments described in the examples below, compositions and related methods comprising a first combination of one or more of theobroma extract, green tea extract, oolong tea extract, white tea extract, caffeine, niacin, and yerba mate extract, and guarana extract;
a second combination of one more of dandelion root extract, juniper berry powder, parsley powder (leaf), cayenne pepper powder, and xanthinol nicotinate;
a third combination of one or more of N-acetyl-L-tyrosine, gynostemma pentaphyullum extract, and vinpocetine. Additionally, the present invention may also comprise thiamin, pyridoxine, picamilone, garcinia cambogia extract, and/or xanthinol nicotinate.
The compositions according to the present invention may be administered in methods for increasing the natural metabolic rate, burning calories, increasing thermogenesis and decreasing water retention. The methods of the present invention are particularly advantageous for athletes and bodybuilders to improve visible muscular definition. In certain embodiments, the methods of the present invention include a determination, and an administration, of an amount of a composition in accordance with factors such as the desired effect, the body weight and characteristics of the athlete. For example, in certain embodiments, the present invention includes methods of administering compositions according to the invention to subjects on a daily basis or three times daily.
Although the following example illustrates the practice of the present invention in example embodiments, the examples should not be construed as limiting the scope of the invention. Other embodiments will be apparent to one skilled in the art from consideration of the specification and example.
Example 1 As a first example, the following composition is provided: green tea extract (0.4440 g), caffeine anhydrous (0.3000 g), dandelion root powder (0.2500 g), parsley powder (0.2000 g), juniper berry powder (0.2000 g), cayenne pepper powder (0.1000 g), n-acetyl-l-tyrosine (0.1000 g), quercetin dehydrate (0.1000 g), picamilone HCI
(0.1000 g), gynostemma pentaphyullum leaf exact (0.0350 g), niacin (0.0330 g), oolong tea dry leaf extract (0.0100 g), white tea dry leaf extract (0.0100 g), theobroma cocao extract (0.0100 g), vinpocetine (0.0050 g), pyridoxine HCI (0.0020 g), thiamin mononitrate (0.0015 g), guarana powder (0.0010 g), yerba mate leaf powder (0.0010 g), gelatin, titanium dioxide, microcrystalline cellulose (0.0660 g), magnesium stearate (0.0330 g), and silica (0.0165 g).
The example composition may be ingested 30 to 60 minutes prior to eating a meal. The example composition can also be consumed prior exercise to increase and athlete's training intensity.
Example 2 As a second example, the following composition is provided: green tea extract (0.440 g), caffeine anhydrous (0.3000 g), dandelion root powder (0.2500 g), parsley powder (0.2000 g), juniper berry powder (0.200), cayenne pepper powder (0.100 g), n-acetyl-I-tyrosine (0.1000 g), quercetin dehydrate (0.1000 g), xanthinol nicotinate (0.1000 g), gynostemma pentaphyullum leaf exact (0.0350 g), niacin (0.0330 g), oolong tea dry leaf extract (0.0100 g), white tea dry leaf extract (0.0100 g), theobroma cocao extract (0.0100 g), vinpocetine (0.0050 g), pyridoxine HCI (0.0020 g), thiamin mononitrate (0.0015 g), guarana powder (0.0010 g), yerba mate leaf powder (0.0010), gelatin, titanium dioxide, microcrystalline cellulose (0.0660), magnesium stearate (0.0330 g), and silica (0.0165 g).
The example composition may be ingested 30 to 60 minutes prior to eating a meal. The example composition can also be consumed prior exercise to increase and athlete's training intensity.
Claims (14)
1. A composition comprising at least two of:
a first combination that comprises Green Tea Extract, Anhydrous Caffeine, and Guarana Extract;
a second combination that comprises Dandelion Root Extract, and Juniper Berry Powder; and a third combination that comprises N-Acetyl-L-Tyrosine, and Gynostemma Pentaphyullum.
a first combination that comprises Green Tea Extract, Anhydrous Caffeine, and Guarana Extract;
a second combination that comprises Dandelion Root Extract, and Juniper Berry Powder; and a third combination that comprises N-Acetyl-L-Tyrosine, and Gynostemma Pentaphyullum.
2. A composition according to claim 1 furthering comprising Thiamin.
3. A composition according to claim 1 furthering comprising Pyridoxine.
4. A composition according to claim 1 furthering comprising Niacin.
5. A composition according to claim 1 further comprising Picamilone.
6. A composition according to claim 1 further comprising Xantinol Nicotinate.
7. A composition according to claim 1 further comprising Garcinia Cambogia extract.
8. A method for increasing the natural metabolic rate, burning calories, increasing thermogenesis or decreasing water retention in a subject comprising administering to the subject a composition according to claim 1.
9. A method for increasing the natural metabolic rate, burning calories, increasing thermogenesis or decreasing water retention in a subject comprising administering to the subject a composition according to claim 2.
10.A method for increasing the natural metabolic rate, burning calories, increasing thermogenesis or decreasing water retention in a subject comprising administering to the subject a composition according to claim 3.
11.A method for increasing the natural metabolic rate, burning calories, increasing thermogenesis or decreasing water retention in a subject comprising administering to the subject a composition according to claim 4.
12.A method for increasing the natural metabolic rate, burning calories, increasing thermogenesis or decreasing water retention in a subject comprising administering to the subject a composition according to claim 5.
13.A method for increasing the natural metabolic rate, burning calories, increasing thermogenesis or decreasing water retention in a subject comprising administering to the subject a composition according to claim 6.
14.A method for increasing the natural metabolic rate, burning calories, increasing thermogenesis or decreasing water retention in a subject comprising administering to the subject a composition according to claim 7.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66339605P | 2005-03-18 | 2005-03-18 | |
| US60/663,396 | 2005-03-18 | ||
| PCT/CA2006/000415 WO2006096996A1 (en) | 2005-03-18 | 2006-03-20 | Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2600301A1 true CA2600301A1 (en) | 2006-09-21 |
Family
ID=36991257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002600301A Abandoned CA2600301A1 (en) | 2005-03-18 | 2006-03-20 | Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1863433A4 (en) |
| AU (1) | AU2006225005A1 (en) |
| CA (1) | CA2600301A1 (en) |
| WO (1) | WO2006096996A1 (en) |
| ZA (1) | ZA200708361B (en) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070015686A1 (en) * | 2005-07-07 | 2007-01-18 | Heuer Marvin A | Dietary supplement for enhancing skeletal muscle mass, decreasing muscle protein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells |
| US20210077517A1 (en) * | 2008-06-13 | 2021-03-18 | International IP Holdings | Edible Energy Composition |
| US10881661B2 (en) * | 2008-06-13 | 2021-01-05 | International Ip Holdings Llc | Edible energy composition |
| FR2938735B1 (en) * | 2008-11-21 | 2012-12-28 | Holymark | AMAIGRANT COMPOSITION, ESPECIALLY FOR SPORTS, ORAL ADMINISTRABLE AND FOOD SUPPLEMENT INTEGRATING SUCH A COMPOSITION. |
| CN102802626B (en) | 2009-06-11 | 2015-11-25 | 帝斯曼知识产权资产管理有限公司 | Niacin and/or Trigonelline as muscle stimulants |
| ES2386858B1 (en) * | 2011-02-07 | 2013-03-22 | Eduardo Antonio Gómez De Diego | NATURAL SLIMMING COMPOSITION. |
| WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
| WO2013168019A1 (en) * | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neuropathic pain |
| EP2847158A4 (en) | 2012-05-07 | 2015-12-30 | Cellix Bio Private Ltd | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders |
| SG11201407300VA (en) | 2012-05-07 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of neurological disorders |
| WO2013167990A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of depression |
| US9309233B2 (en) | 2012-05-08 | 2016-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of blood clotting disorders |
| WO2013168023A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of parkinson's disease |
| US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
| WO2013167992A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory disorders |
| WO2013167993A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological degenerative disorders |
| WO2013168011A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of chronic pain |
| US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| US9403857B2 (en) | 2012-05-10 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
| WO2013167997A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168005A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
| WO2013168033A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neurologic diseases |
| US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
| WO2013168000A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of severe pain |
| US9394288B2 (en) | 2012-05-10 | 2016-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of asthma and allergy |
| US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
| WO2013168004A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of fibromyalgia pain |
| WO2013168001A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| WO2013175376A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of local pain |
| CA2873098A1 (en) | 2012-05-23 | 2013-11-28 | Cellixbio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| WO2013175344A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
| SG11201407326XA (en) | 2012-05-23 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for treatment of mucositis |
| SG11201407319YA (en) | 2012-05-23 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for treatment of inflammatory bowel disease |
| US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| WO2014020480A2 (en) | 2012-08-03 | 2014-02-06 | Mahesh Kandula | Compositions and methods for the treatment migraine and neurologic diseases |
| WO2014037833A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment inflammation and lipid disorders |
| CA2873029A1 (en) | 2012-09-08 | 2014-03-13 | Cellixbio Private Limited | Compositions and methods for the treatment of inflammation and lipid disorders |
| US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| SG11201509782TA (en) | 2013-06-04 | 2015-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of diabetes and pre-diabetes |
| US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
| CA2976314C (en) | 2014-09-26 | 2021-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
| CA2967908C (en) | 2014-09-29 | 2020-11-17 | Mahesh Kandula | Compositions and methods for the treatment of multiple sclerosis |
| JP6564868B2 (en) | 2014-10-27 | 2019-08-21 | セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ | Three component salts of fumaric acid monomethyl ester and piperazine or ethylenediamine for the treatment of multiple sclerosis |
| US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
| US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
| US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
| US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
| US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
| CN110845355A (en) | 2015-01-06 | 2020-02-28 | 塞尔利克斯生物私人有限公司 | Compositions and methods for treating inflammation and pain |
| US12285456B2 (en) | 2018-03-20 | 2025-04-29 | Exerkine Corporation | Weight management composition |
| CA3050823C (en) * | 2018-03-20 | 2021-02-23 | Mark TARNOPOLSKY | Weight management composition |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277396B1 (en) * | 2000-05-11 | 2001-08-21 | Maximum Human Performance, Inc. | Dietary supplement containing a thermogenic substance and an adrenal support substance |
| US7670612B2 (en) * | 2002-04-10 | 2010-03-02 | Innercap Technologies, Inc. | Multi-phase, multi-compartment capsular delivery apparatus and methods for using same |
| US20040005368A1 (en) * | 2002-07-01 | 2004-01-08 | Morris Mann | Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite |
-
2006
- 2006-03-20 EP EP06741359A patent/EP1863433A4/en not_active Withdrawn
- 2006-03-20 WO PCT/CA2006/000415 patent/WO2006096996A1/en not_active Ceased
- 2006-03-20 AU AU2006225005A patent/AU2006225005A1/en not_active Abandoned
- 2006-03-20 CA CA002600301A patent/CA2600301A1/en not_active Abandoned
-
2007
- 2007-10-01 ZA ZA200708361A patent/ZA200708361B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006096996A1 (en) | 2006-09-21 |
| EP1863433A1 (en) | 2007-12-12 |
| AU2006225005A1 (en) | 2006-09-21 |
| ZA200708361B (en) | 2008-10-29 |
| EP1863433A4 (en) | 2009-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2600301A1 (en) | Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition | |
| US20050249827A1 (en) | Nutritional composition which promotes weight loss, burns calories, increases thermogenesis, supports energy metabolism and/or suppresses appetite | |
| US7989009B2 (en) | Composition and method for promoting weight loss | |
| AU2019200802B2 (en) | Synergistic dietary supplement compositions for enhancing physical performance | |
| US9220741B2 (en) | Weight loss formulation | |
| US7955624B2 (en) | Compositions and methods for increasing adipose metabolism, lipolysis or lipolytic metabolism via thermogenesis | |
| US20060210653A1 (en) | Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition | |
| Cherniack | Potential applications for alternative medicine to treat obesity in an aging population | |
| US7943183B2 (en) | Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition | |
| WO2018112475A1 (en) | Energy compositions and methods | |
| US20040097429A1 (en) | Method for the reduction of the mammalian appetite | |
| US20130280367A1 (en) | Method and Composition for Increasing Energy and Focus | |
| CA2751218C (en) | Weight loss formulation | |
| US20080279967A1 (en) | Composition and method for increasing the metabolism of free fatty acids and facilitating a favorable blood lipid | |
| US7390513B2 (en) | Food supplement formulation | |
| WO2011159850A2 (en) | Lip cosmetic formulations | |
| PT103650B (en) | COMPOSITIONS OF VEGETABLE EXTRACTS | |
| KR20050038766A (en) | New synergetic compositions of vitamins, minerals and trace-elements to stimulate the elimination of intra-cellular lipid deposits |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |